Arginine Starvation Boosts OS in Mesothelioma
(MedPage Today) -- First-line chemotherapy plus an investigational arginine-depleting agent improved survival in nonepithelioid pleural mesothelioma compared with chemotherapy alone, a randomized trial showed.
For the study's primary endpoint... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news
Perioperative Tislelizumab Demonstrates Survival Benefit in NSCLC
(MedPage Today) -- Adding tislelizumab to neoadjuvant chemotherapy followed by adjuvant use of the investigational PD-1 inhibitor improved event-free survival (EFS) in resectable non-small cell lung cancer (NSCLC), a phase III trial from China... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 16, 2024 Category: Hematology Source Type: news
Tracing the Progress of Treatment Strategies in Diffuse Large B-Cell Lymphoma Tracing the Progress of Treatment Strategies in Diffuse Large B-Cell Lymphoma
Dr. Kami Maddocks explores the transformation of treatment approaches for DLBCL from chemotherapy-based strategies to targeted therapies.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 15, 2024 Category: Consumer Health News Tags: Hematology-Oncology MDAngle Source Type: news
Drug offers ‘wonderful’ breakthrough in treatment of asbestos-linked cancer
Medicine used alongside chemotherapy in trials quadrupled three-year survival rates for mesotheliomaScientists have developed a drug to treat mesothelioma, a notoriously hard-to-treat cancer linked to asbestos, in the biggest breakthrough in two decades.Thousands of people are diagnosed with the disease globally every year, which tends to develop in the lungs and ismainly caused by exposure to asbestos at work. It is aggressive and deadly, and has one of the world ’s worst cancer survival rates.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - February 15, 2024 Category: Science Authors: Andrew Gregory Health editor Tags: Cancer research Health Medical research Science Society Queen Mary, University of London UK news Source Type: news
US Agencies Start Inquiry Into Generic Drug Shortages
The F.T.C. and H.H.S. are examining the tactics of group purchasing organizations that generic industry executives say have led to scarce supplies of treatments like chemotherapy. (Source: NYT Health)
Source: NYT Health - February 14, 2024 Category: Consumer Health News Authors: Christina Jewett Tags: Shortages Drugs (Pharmaceuticals) Supply Chain Generic Brands and Products Chemotherapy Federal Trade Commission Health and Human Services Department Khan, Lina Source Type: news
Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer Include Neoadjuvant Chemotherapy in Stage II-III Lung Cancer
Mark Kris, MD, discusses the use of a checkpoint inhibitor and chemotherapy as neoadjuvant therapy for every patient with stage II and III lung cancer at the time of diagnosis.Medscape Oncology (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 14, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Commentary Source Type: news
Pembrolizumab Improves Event-Free Survival in Early NSCLC
TUESDAY, Feb. 13, 2024 -- For patients with early-stage non-small cell lung cancer (NSCLC), event-free survival (EFS) is improved with neoadjuvant pembrolizumab and chemotherapy, according to a study presented at the annual meeting of The Society of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 13, 2024 Category: Pharmaceuticals Source Type: news
FLT3 Inhibitor Highly Active in Newly Diagnosed Acute Myeloid Leukemia
(MedPage Today) -- Patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML) had a high response rate and prolonged event-free survival (EFS) following treatment with an investigational FLT3 inhibitor and chemotherapy, a preliminary... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 13, 2024 Category: Hematology Source Type: news
Early Detection Tests for Mesothelioma Are in Development
Scientists in Australia are developing early detection tests for mesothelioma. The Asbestos and Dust Diseases Research Institute’s new test could potentially save lives. According to ADDRI’s academic and research director Dr. Anthony Linton, the tests will be similar to PCR tests already in use to detect COVID-19.
These new tests can find small amounts of DNA that cause disease. The PCR method, used since the 1980s, allows DNA samples to be studied in a higher level of detail. PCR is the tech behind the beginning of the 1990 Human Genome Project to identify and map human DNA.
“We have identified a...
Source: Asbestos and Mesothelioma News - February 13, 2024 Category: Environmental Health Authors: Travis Rodgers Tags: Asbestos Exposure Clinical Trials/Research/Emerging Treatments Doctors/Specialists Mesothelioma Source Type: news
Quebec cancer center first in Canada to use Accuray's Radixact system
Montérégie Integrated Cancer Center in Quebec, Canada, part of Charles-LeMoyne Hospital, is the first center in the country to treat cancer patients using Accuray's Radixact radiation therapy delivery system.
A second Radixact system is scheduled to be installed at the center later in 2024. The system at the Montérégie center also incorporates the Accuray exclusive ClearRT helical fan-beam kVCT imaging solution and Synchrony motion adaptation technology. Combined, this allows for clinicians to acquire diagnostic-like quality CT images along with tracking, detecting, and correcting for tumor movement in real-time, the ...
Source: AuntMinnie.com Headlines - February 13, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Fruquintinib + Paclitaxel Aids Advanced Gastric/Gastroesophageal Junction Cancer
MONDAY, Feb. 12, 2024 -- For patients with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma who experienced disease progression on first-line chemotherapy, fruquintinib (F) plus paclitaxel (PTX) improves progression free survival... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 12, 2024 Category: Pharmaceuticals Source Type: news
Add-On Fruquintinib Delays Progression in Gastric Cancer Add-On Fruquintinib Delays Progression in Gastric Cancer
Fruquintinib plus paclitaxel improves cancer progression-free, but not overall survival, in patients with gastric/gastroesophageal cancer who have progressed on frontline chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 12, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
RaySearch takes full ownership of DrugLog's oncology product
RaySearch announced a 7-million-SEK ($670 million U.S.) deal with Pharmacolog AB for full ownership of DrugLog, a system that tracks the content and concentration of liquid medicine, such as chemotherapy.
In the announcement, RaySearch founder and CEO Johan Löf said the company will add DrugLog to treatment planning in RayStation and workflows in RayCare for chemotherapy management. Löf added that adding DrugLog will improve and simplify quality assurance in cancer treatment with chemotherapy.
The deal is specific to oncology and includes the measuring device, calibration parameters, source code, and intellectual prope...
Source: AuntMinnie.com Headlines - February 9, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
Why 2023 was the 'worst year' for cancer: Record high 30,000 patients were made to wait at least a month to start NHS treatment, 'alarming' data reveals
Over 30,000 people waited more than a month after being told they needed the likes of surgery, chemotherapy or radiotherapy, 'alarming' new data from NHS England reveals. (Source: the Mail online | Health)
Source: the Mail online | Health - February 8, 2024 Category: Consumer Health News Source Type: news
Mixed Results in Advanced Gastric/GEJ Cancer With Add-On Fruquintinib
(MedPage Today) -- Adding a targeted agent to second-line chemotherapy significantly improved progression-free survival (PFS) but not overall survival (OS) in advanced gastric cancer, a large randomized trial showed.
Pairing the angiogenesis inhibitor... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - February 7, 2024 Category: Gastroenterology Source Type: news
